Clinical significance of mtor and p-mtor protein expression in human colorectal carcinomas

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 10, 2011, Pages 2581-2584

  Wang, Di ^a,b   Chen, Jian ^b   Guo, Fengjie ^b   Chen, Hui ^b   Duan, Zhi ^b   Wei, Mei Yan ^b   Xu, Qi Mei ^b   Wang, Liang Hua ^b   Zhong, Mei Zuo ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Changsha First Hospital   (China)

Author keywords

Colorectal cancer; Immunohistochemistry; Mtor; Overexpession; P

Indexed keywords

EID: 84863268462     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Buck E, Eyzaguirre A, Brown E, et al (2006). Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther, 5, 2676-84.
2. Chung JY, Hong SM, Choi BY, et al(2009). The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res, 15, 660-7.
3. DobashiY, Suzuki S, Matsubara H, et al (2009). Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer, 115, 107-18.
4. Feng W, Duan X, Liu J, Xiao J, Brown RE (2009). Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol, 2, 249-60.
5. Foster DA (2009). Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim Biophys Acta, 1791, 949-55.
6. Herberger B, Puhalla H, Lehnert M, et al (2007). Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res, 13, 4795-9.
7. Ji J, Zheng PS (2010). Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol, 117, 103-8.
8. Jiang BH, Liu LZ (2008). Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat, 11, 63-76.
9. Kremer CL, Klein RR, Mendelson J, et al (2006). Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate, 66, 1203-12.
10. No JH, JeonYT, Park IA, et al (2009). Expression of mTOR protein and its clinical significance in endometrial cancer. Med Sci Monit, 15, BR301-5.
11. O'Donnell A, Faivre S, Burris HA III, et al (2008). Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol, 26, 1588-95.
12. Otake S, Takeda H, Fujishima S, et al (2010). Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol, 16, 1252-7.
13. Pantuck AJ, Seligson DB, Klatte T, et al (2007). Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer, 109, 2257-67.
14. Pham NA, Schwock J, Iakovlev V, et al (2008). Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer, 8, 43.
15. Raymond E, Alexandre J, Faivre S, et al (2004). Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol, 22, 2336-47.
16. Rizell M, Andersson M, Cahlin C, et al (2008). Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol, 13, 66-70.
17. Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O (2010). Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer, 9, 57.
18. Shaw RJ, Cantley LC (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 441, 424-30.
19. Yu G, Wang J, ChenY, et al (2009). Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res, 15, 1821-9.